An immunotherapy technology developed by Dr. Brian Till with Dr. Oliver Press at Fred Hutchinson Cancer Research Center has been licensed by Mustang Bio Inc., a subsidiary of the biopharmaceutical company Fortress Biotech Inc. The exclusive, worldwide license, announced Sept. 14 by Mustang Bio, will allow a new type of CAR (chimeric antigen receptor) T-cell therapy to be tested in a clinical trial as a treatment for B-cell non-Hodgkin lymphomas. The novel immunotherapy targets CD20, a protein marker on cancer cells in lymphoma.
A biopolymer sponge delivers cancer-shrinking T-cell therapy in preclinical study
April 24, 2017
| By Sabrina Richards / Fred Hutch News Service
A dissolving scaffold developed by Dr. Matthias Stephan delivers engineered anti-tumor immune cells to crowded masses of tumor cells and recruits the native immune system to mount a second-wave attack on the cancer.
‘Tumor microenvironment’ poses unique challenges for T-cell therapy in solid tumors
April 4, 2017
| By Rachel Tompa / Fred Hutch News Service
A major roadblock to adopting T-cell therapy to solid tumors is what’s known as the tumor microenvironment, the local milieu of non-cancerous cells and molecules in and around the tumor. Fred Hutch researcher Dr. Kristin Anderson and her colleagues in Dr. Phil Greenberg's lab are working to overcome those barriers.